

ORIGINAL PAPER



Conservative management of cervical intraepithelial neoplasia 2 and prediction of its progression – a retrospective study

ALEXANDRU CĂRĂULEANU¹⁾, RALUCA ANAMARIA MOGOȘ^{1,2)}, IUSTINA PETRA SOLOMON-CONDRIUC^{1,2)}, CLAUDIA FLORIDA COSTEA³⁾, ANDREI IONUȚ CUCU^{4,5)}, ȘTEFANA RALUCA BRAN⁶⁾, ADINA ELENA TĂNASE¹⁾, GABRIEL VALENTIN TĂNASE⁷⁾, ELENA ANDREEA PRUTEANU¹⁾, DEMETRA GABRIELA SOCOLOV¹⁾, FLORIN DUMITRU PETRARIU⁸⁾, CĂTĂLIN MIHAI BUZDUGĂ⁹⁾

¹⁾Department of Obstetrics and Gynecology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

²⁾Doctoral School, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

³⁾Department of Surgery II, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

⁴⁾Department of Biomedical Sciences, Faculty of Medicine and Biological Sciences, Ștefan cel Mare University of Suceava, Romania

⁵⁾2nd Neurosurgery Clinic, Prof. Dr. Nicolae Oblu Emergency Clinical Hospital, Iași, Romania

⁶⁾PhD Student, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

⁷⁾Department of Anesthesiology and Intensive Care, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

⁸⁾Department of Preventive Medicine and Interdisciplinarity, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

⁹⁾Department of Endocrinology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

Abstract

Aim: Cervical intraepithelial neoplasia 2 (CIN2) evolution is controversial, and some of them regress spontaneously in a two-year follow-up. The purpose of this work was to evaluate the percentage of CIN2 progression or persistence during a 24-month follow-up, using clinical predictors such as human papillomavirus (HPV) genotype and cytology results. **Patients, Materials and Methods:** This is a retrospective case-control study and included patients of reproductive age who had a new diagnosis of CIN2 who were monitored for lesion regression (Group 1, $n=72$ patients), and progression or persistence (Group 2, $n=36$ patients). A multinomial logistic regression was preferred to evaluate the impact that various categorical risk elements can lead to outcomes of persistence or progression of CIN2. We also performed a linear regression to assess the risk of CIN2 progression or persistence using the interaction between clinical predictors. **Results:** A previous cervical cytology indicative of high-grade squamous intraepithelial lesion (HSIL) [relative risk ratio (RRR): 3.85, 95% confidence interval (CI): 1.66–8.90] or atypical squamous cells, cannot exclude HSIL (ASC-H) can highly raise the probability of a CIN2 progression or persistence. The presence of HPV16 increased the risk of CIN2+ with 3.77 (95% CI: 0.78–5.00), the presence of HPV18 increased the probability of CIN2+ with 4.39 (95% CI: 1.35–14.33), and other high-risk HPV (HR-HPV) strains increased the probability of CIN2+ with 3.62. The highest risk issue was produced by the interaction between HSIL * HPV16, ASC-H* HPV16, and ASC-H* HPV18. **Conclusions:** When discussing follow-up for CIN2 lesions, it is important to offer careful consideration and monitoring of patients with a previous HSIL or ASC-H cytology, with or without HPV 16, 18 or other HR-HPV strains, as their presence significantly increased the risk of CIN2 progression and persistence.

Keywords: cervix, colposcopy, HPV, Pap smear, biopsy.

Introduction

The human papillomavirus (HPV) tends to be one of the leading pathogens to cause cervical dysplasia, covering up to 99% of the main factors in epithelial dysplasia [1]. Intraepithelial lesions are described in three categories based on the epithelial layer damage. Cervical intraepithelial neoplasia 1 (CIN1) is considered to be a low-grade squamous intraepithelial lesion (LSIL) concerning 1/3 of the basal epithelium, with high chances of recovery, also meaning a LSIL in Pap smear results [2]. Regression often occurs in the first two years following the infection and no surgical treatment is required if cervical biopsy shows limited lesions [3, 4].

CIN2 and CIN3 are considered to be high-grade squamous intraepithelial lesions (HSILs). The associated Pap smear results correspond to HSIL, atypical glandular cells (AGCs) or *in situ* neoplastic lesions [5]. CIN2 is considered moderate dysplasia that affects 2/3 of the basal epithelium, while for CIN3, the results correspond to severe dysplasia with high chances of neoplastic cells, because the affected areas are considered to fully occupy the epithelial layers with intact basal membrane [6]. In this case, some of the lesions are called *in situ* carcinoma.

Considering medical treatment, the first step in counseling is primary prevention. Primary prevention consists in HPV vaccination, since early ages, before the onset of sexual life. Nowadays, three vaccines are offered for primary

vaccination: Gardasil, a quadrivalent vaccine protecting against HPV 6 and 11 low oncogenic types and HPV 16 and 18 that cause more than 70% of cervical cancer forms [7]. Three doses are necessary to achieve full immunization.

As for a second vaccine, we have Cervarix, a bivalent vaccine offering protection for HPV 16 and 18, divided in three doses [7]. The most complex vaccine is considered to be Gardasil 9, a nonvalent form that offers protection against nine subtypes of HPV (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) divided in three doses [7, 8]. Romania had a poor preventive result in the early 90's in early ages, but nowadays the government is promoting low prices, in order to be accessible for a wide population with ages between 9–45 years old [9–12].

Although vaccination offers a good protection, considering that countries where vaccination was successful, have very low rates of cervical neoplasia, we cannot ignore recommendations for further Pap smear and HPV testing. When HPV testing alone is negative, the recommendation is to test the patients after three years. If the HPV test is positive, annual testing is required, associated with cytology result and colposcopy recommendation [1, 13].

Patients diagnosed with CIN1/LSIL are often managed conservatively, as around 80% of these lesions exhibit spontaneous regression [14]. Conversely, excisional therapy is the optimal choice for CIN3 because of its elevated risk of progressing to cervical cancer. CIN2, categorized as HSIL on cytology report, has a debatable management because of spontaneous progression or regression rates of approximately 11–18% and 50–61%, respectively, after 24 months of follow-up [15].

Aim

Due to the absence of well-defined risk indicators for predicting disease progression complicates the therapy of CIN2. This study aimed to assess the risk of CIN2 progression or persistence during a 24-month follow-up using clinical predictors such as HPV genotype and cytology results.

Patients, Materials and Methods

This retrospective observational case-control analysis included patients of reproductive age with a new diagnosis of CIN2 who attended Noelle Clinic in Iași, Romania, between July 2021 and July 2024.

The inclusion criteria comprised the following: age between 25 and 45 years old; patients who opted for watch and wait management; patients who had a CIN2 histological diagnosis; providing informed consent for data collection. The exclusion criteria comprised the following: inadequate colposcopy evaluation of the cervical lesions; primary diagnosis of CIN2+; loss of follow-up.

All our patients were treated in accordance with the prevailing guidelines and received cytology and colposcopy evaluations biannually for a duration of two years. Cervical biopsy was conducted according to the national regulations.

When the biopsy indicated CIN3, patients were subjected to prompt intervention through the loop electrosurgical excision procedure. A complete regression was considered, when two successive cervical cytology, colposcopy, and biopsy findings indicated no lesion, a partial regression if the final biopsy revealed CIN1, the persistence of the lesion was considered when a biopsy at 24 months of follow-up indicated CIN2, and the lesion progression was

considered if a CIN3 lesion was identified at a biopsy performed anytime during the follow-up.

The main outcomes were considered the following: regression (partial/complete) and persistence of progression (CIN2+) and corresponded to the main study groups: Group 1 ($n=72$) and Group 2 ($n=36$).

Cervical cells were collected in ThinPrep vials for liquid-based cytology and further HPV genotyping. The cervical cytology was classified according to the Bethesda system, and HPV genotyping was done using real-time polymerase chain reaction (PCR) and nucleic acid hybridization.

The histopathological specimens from cervical biopsies and conizations were described according to the *World Health Organization* (WHO) criteria.

Descriptive statistics using Pearson's χ^2 (*chi-squared*) test were employed for assessing the difference regarding the categorical variables rates. A multinomial logistic regression was used to assess the impact of various categorical risk factors on the outcome of persistence or progression of CIN2. The analysis was adjusted for potential confounders, and the results were reported as relative risk ratios (RRRs) and 95% confidence intervals (CIs). We also performed a linear regression to assess the risk of CIN2 progression or persistence using the interaction between clinical predictors and reports the results as standardized coefficients (StdCs). Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS; version 25.0, IBM Corp., Armonk, NY, USA). A p -value less than 0.05 was considered statistically significant.

Results

Data from a total of 108 patients that completed the 24 months follow-up was used for analysis in this study. Fifty-one (47.22%) patients had a CIN2 complete regression, 21 (19.44%) patients had a partial regression, 22 (20.37%) patients had CIN2 persistence, and 14 (12.96%) patients had CIN2 progression. The main groups further analyzed were represented by Group 1 (partial/complete regression, 72 patients) and Group 2 (CIN2 progression and persistence, 36 patients). Their clinical characteristics are presented in Table 1 and were as follows: age (in years), parity, if they were using, or not, contraception, smokers or not, vaccinated or not, if they had previous cytological evaluation and HPV genotyping. The data were correlated with the first group, totaling a number of 72 patients and with Group 2, consisting of 36 patients.

Our results indicated that the study groups were relatively homogenous considering their clinical characteristics such as age ($p=0.86$), parity ($p=0.82$), use of contraceptive methods ($p=0.77$), smokers ($p=0.19$), and vaccination status ($p=0.68$). However, the second group of patients had significantly higher rates of HPV16 (47.22% *versus* 31.94%) and HPV18 infections (25% *versus* 6.94%) compared to the first group ($p=0.003$). Also, patients who later had a progression or persistence of HPV infection, had higher rates of HSIL on cytological examinations (63.88% *versus* 33.33%, $p=0.004$).

We used a multinomial logistic regression to evaluate the risk of CIN2 progression or persistence using clinical predictors, and the results are showed in Table 2. Our results indicated that a previous cervical cytology indicative of HSIL (RRR: 3.85, 95% CI: 1.66–8.90, $p=0.02$) or atypical squamous cells, cannot exclude HSIL (ASC-H) (RRR: 1.54, 95% CI: 1.25–1.89, $p=0.03$) significantly increased the risk

of CIN2 progression or persistence. Moreover, the presence of HPV16 increased the risk of CIN2+ with 3.77 (95% CI: 0.78–5.00, $p<0.001$), the presence of HPV18 increased the

risk of CIN2+ with 4.39 (95% CI: 1.35–14.33, $p=0.014$), and other high-risk HPV (HR-HPV) strains increased the risk of CIN2+ with 3.62 (95% CI: 1.55–8.49, $p=0.003$).

Table 1 – Clinical characteristics of the study groups

Clinical characteristics	Group 1 (partial/complete regression, n=72)	Group 2 (CIN2 progression and persistence, n=36)	p-value
Age, years (mean ± SD)	31.72±4.31	32.40±4.79	0.86
Parity, n (%)	Nulliparous: 31 (43.66%)	Nulliparous: 16 (44.44%)	0.82
	Multiparous: 40 (56.33%)	Multiparous: 20 (55.55%)	
Contraception, n (%)	Yes: 23 (31.94%)	Yes: 10 (27.77%)	0.77
Smokers, n (%)	Yes: 29 (40.27%)	Yes: 19 (52.77%)	0.19
Vaccination, n (%)	Yes: 13 (18.05%)	Yes: 8 (22.22%)	0.68
Previous cytology, n (%)	ASCUS: 16 (22.22%)	ASCUS: 4 (11.11%)	0.004
	LSIL: 17 (23.61%)	LSIL: 8 (22.22%)	
	HSIL: 24 (33.33%)	HSIL: 23 (63.88%)	
	ASC-H: 15 (20.83%)	ASC-H: 1 (2.77%)	
HPV genotyping, n (%)	HPV16: 23 (31.94%)	HPV16: 17 (47.22%)	0.003
	HPV18: 5 (6.94%)	HPV18: 9 (25%)	
	Other HR-HPV: 43 (61.11%)	Other HR-HPV: 11 (30.55%)	

ASC-H: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); ASCUS: Atypical squamous cells of undetermined significance; CIN2: Cervical intraepithelial neoplasia 2; HPV: Human papillomavirus; HR: High risk; LSIL: Low-grade squamous intraepithelial lesion; n: No. of patients; SD: Standard deviation.

Table 2 – Multinomial logistic regression to assess the risk of CIN2 progression or persistence using clinical predictors

Predictor	RRR	95% CI	p-value
ASCUS	2.40	0.73–7.79	0.140
LSIL	1.14	0.43–2.96	0.780
HSIL	3.85	1.66–8.90	0.020
ASC-H	1.54	1.25–1.89	0.030
HPV16	3.77	0.78–5.00	<0.001
HPV18	4.39	1.35–14.33	0.014
Other HR-HPV	3.62	1.55–8.49	0.003

ASC-H: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); ASCUS: Atypical squamous cells of undetermined significance; CI: Confidence interval; CIN2: Cervical intraepithelial neoplasia 2; HPV: Human papillomavirus; HR: High risk; LSIL: Low-grade squamous intraepithelial lesion; RRR: Relative risk ratio.

We used a linear regression to evaluate the risk of CIN2 progression or persistence using the interaction between the cytology results and interaction effects, and the results are presented in Table 3.

Table 3 – Linear regression to assess the risk of CIN2 progression or persistence using interaction between clinical predictors

Interaction effect	StdC	SE	p-value
ASCUS* HPV16	0.70	0.08	0.46
ASCUS* HPV18	0.72	0.09	0.32
ASCUS* HR-HPV	1.42	0.10	<0.001
LSIL* HPV16	0.98	0.10	0.89
LSIL* HPV18	3.12	0.81	<0.001
LSIL* HR-HPV	1.09	0.27	0.70
HSIL* HPV16	1.78	0.18	<0.001
HSIL* HPV18	1.43	0.11	0.002
HSIL* HR-HPV	1.55	0.25	0.008
ASC-H* HPV16	1.88	0.12	<0.001
ASC-H* HPV18	1.92	0.09	<0.001
ASC-H* HR-HPV	1.67	0.10	<0.001

ASC-H: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); ASCUS: Atypical squamous cells of undetermined significance; CIN2: Cervical intraepithelial neoplasia 2; HPV: Human papillomavirus; HR: High risk; LSIL: Low-grade squamous intraepithelial lesion; SE: Standard error; StdC: Standardized coefficient.

Our results indicated that the highest risk increment was determined by the interaction between HSIL* HPV16 [StdC: 1.78, standard error (SE): 0.18, $p<0.001$], ASC-H* HPV16 (StdC: 1.88, SE: 0.12, $p<0.001$), and ASC-H* HPV18 (StdC: 1.92, SE: 0.09, $p<0.001$).

Discussions

HR-HPV subtypes 16 and 18 are the main cause for more than half of untreated cervical cancers. They are mostly associated with HSILs, but endocervix adenocarcinoma occurs especially in HPV18-positive patients [16].

In a review assessing cervical dysplasia, the authors evaluated the gynecological management associated with the risk of progression to cervical pathology. They found that patients who were managed with both Pap smear and HPV testing had better follow-up strategies and lower risk of CIN2+ progression, compared to women who were managed with only one of the previous methods [17]. In our study, we investigated the risk of CIN2 progression or persistence during a 24-month follow-up using clinical predictors such as HPV genotype and cytology results. Our results showed that a previous cervical cytology indicative of HSIL or ASC-H significantly increased the risk of CIN2 progression or persistence. Moreover, the presence of HPV16 increased the risk of CIN2+ with 3.77, the presence of HPV18 increased the risk of CIN2+ with 4.39, and other HR-HPV strains increased the risk of CIN2+ with 3.62. When we studied the cumulative effect of various combinations of cervical cytology reports and HPV genotypes, we found out that highest risk increment was determined by the interaction between HSIL* HPV16, ASC-H* HPV16, and ASC-H* HPV18.

Our results are close with previously published evaluations. For example, research conducted by Salvadó *et al.* that followed-up 291 patients demonstrated that HPV16 infection [odds ratio (OR): 1.97, 95% CI: 1.13–3.43] and previous HSIL cytology (OR: 3.46, 95% CI: 1.99–6.02) significantly increased the risk of persistence or progression of CIN2 lesions [18]. Moreover, Khan *et al.*, conducted a cohort study in a 10-years’ timeframe that examined the risk

stratification of cervical lesions based on HPV genotype [19]. The authors included a total of 20 810 women in the study and demonstrated a global incidence of 17.2% of CIN3+ among HPV16+ women and 13.6% among HPV18+ women.

In our study, 47.22% of patients had a CIN2 complete regression, 19.44% patients had a partial regression, 20.37% patients had CIN2 persistence, and 12.96% patients had CIN2 progression. A comprehensive meta-analysis encompassing 36 studies described the outcomes of nonpregnant patients diagnosed with CIN2, who underwent conservative management at various follow-up intervals [20]. At the 24-month mark, 819 out of 1470 (55.71%) untreated women with CIN2 experienced regression to CIN1 or less (CIN1-). In contrast, 334 of 1257 (26.57%) women maintained their CIN2 status, while 282 of 1445 (19.52%) women advanced to CIN3 or more severe conditions (CIN3+) [20].

While it is true that untreated CIN2 could present a greater long-term risk of cervical cancer compared to immediate intervention, the blanket treatment for all CIN2+ cases results in over-treatment and unwarranted complications [21]. One potential consequence following treatment is the heightened likelihood of subfertility. Another is the risk of premature birth during pregnancies. Maintaining fertility is crucial as the age for childbearing is postponed and the trend of having multiple children gains traction. Furthermore, current research indicated that women diagnosed with CIN2 expressed a readiness to pursue conservative treatment [22]. Therefore, if the progression without any treatment of the CIN2 lesion could be known before, will help women with CIN2 in choosing the best solutions for this disease.

In our study, both groups had similar HPV vaccination rates (18.05% versus 22.22%), and these rates were significantly lower than those previously reported in the literature, which confirms the need for improvement of the national vaccination campaigns in Romania and for awareness increase among premenopausal patients for vaccinal options, especially if they are included in high-risk categories for cervical cancer.

Our study has several limitations: small sample size, limited number of clinical predictors and generalizability, retrospective and unicentric design, as well as a low reported vaccinal rate among patients. Multicentric studies should better assess the opportunity for conservative management of CIN2 lesions, especially for young women of reproductive age who did not complete their family planning.

☑ Conclusions

Cervical dysplasia affects an important number of women worldwide regardless of each country's guidelines and follow-up. When considering young women, it is important to know if surgical management will affect future follow up or even further affect their ability to conceive and carry a pregnancy to term. When discussing follow-up for CIN2 lesions, it is important to offer careful consideration and monitoring of patients with a previous HSIL or ASC-H cytology, with or without HPV 16, 18 or other HR-HPV strains, as their presence significantly increased the risk of CIN2 progression and persistence in a two-years' timeframe.

Conflict of interests

The authors declare that they have no conflict of interests.

References

- Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening: a review. *JAMA*, 2023, 330(6):547–558. <https://doi.org/10.1001/jama.2023.13174> PMID: 37552298
- Qi Z, Ding L, Meng D, Liu H, Wang J, Song L, Lyu YJ, Jia HX, Hao M, Tian ZQ, Wang JT. [Relationship between serum folate and CIN1 prognosis and its interaction with HR-HPV infection]. *Zhonghua Zhong Liu Za Zhi*, 2021, 43(8):866–871. <https://doi.org/10.3760/cma.j.cn112152-20200812-00732> PMID: 34407593
- Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, Chargari C, Cruickshank M, Erzenoglu E, Gallio N, Gultekin M, Heller D, Joura E, Kyrgiou M, Madić T, Planchamp F, Regauer S, Reich O, Esat Temiz B, Woelber L, Zozdika J, Stockdale C. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus Statement on the management of vaginal intraepithelial neoplasia. *J Low Genit Tract Dis*, 2023, 27(2):131–145. <https://doi.org/10.1097/LGT.0000000000000732> PMID: 36951985 PMID: PMC10026974
- Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. *Gynecol Oncol*, 2008, 110(3 Suppl 2):S4–S7. <https://doi.org/10.1016/j.ygyno.2008.07.045> PMID: 18760711
- Loopik DL, Bentley HA, Eijgenraam MN, Int'Hout J, Bekkers RLM, Bentley JR. The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: a systematic review and meta-analysis. *J Low Genit Tract Dis*, 2021, 25(3):221–231. <https://doi.org/10.1097/LGT.0000000000000604> PMID: 34176914
- Chen C, Xu Y, Huang W, Du Y, Hu C. Natural history of histologically confirmed high-grade cervical intraepithelial neoplasia during pregnancy: meta-analysis. *BMJ Open*, 2021, 11(8):e048055. <https://doi.org/10.1136/bmjopen-2020-048055> PMID: 34417214 PMID: PMC8381303
- Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*, 2015, 64(11):300–304. PMID: 25811679 PMID: PMC4584883
- Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. *Antiviral Res*, 2016, 130:101–109. <https://doi.org/10.1016/j.antiviral.2016.03.016> PMID: 27040313
- Simion L, Rotaru V, Cirimbei C, Gales L, Stefan DC, Ionescu SO, Luca D, Doran H, Chitoran E. Inequities in screening and HPV vaccination programs and their impact on cervical cancer statistics in Romania. *Diagnostics (Basel)*, 2023, 13(17):2776. <https://doi.org/10.3390/diagnostics13172776> PMID: 37685314 PMID: PMC10486539
- Badea M, Baroş A, Bohlîţea RE, Julea IE, Furtunescu FL, Istrate-Ofiţeru AM, Iovan L, Cîrstoiu MM, Burcin MR, Turcan N, Neacşu A, Berceanu C. Modern interdisciplinary monitoring of cervical cancer risk. *Rom J Morphol Embryol*, 2019, 60(2):469–478. PMID: 31658320
- Raţiu AC, Secoşan CA, Balint O, Sas I, Grigoraş D, Iliana RŞ, Jianu AM, Motoc AGM, Pirtea LC. The importance of immunocytochemistry in the detection of high-grade cervical lesions. *Rom J Morphol Embryol*, 2017, 58(4):1151–1156. PMID: 29556603
- Ungureanu C, Socolov DG, Anton G, Moroşan E, Trandafir LM, Lozneanu L, Trandafirescu MF, Cojocaru E. Role of ProEx C immunocytochemistry in cervical high-grade squamous intraepithelial lesions detection. *Rom J Morphol Embryol*, 2021, 62(4):1029–1034. <https://doi.org/10.47162/RJME.62.4.15> PMID: 35673822 PMID: PMC9289693
- Cooper DB, McCathran CE. Cervical dysplasia. 2023 Jul 10. In: StatPearls [Internet]. StatPearls Publishing LLC, Treasure Island, FL, USA, 2024 Jan–. PMID: 28613609
- Willows K, Selk A, Auclair MH, Jim B, Jumah N, Nation J, Proctor L, Iazzi M, Bentley J. 2023 Canadian Colposcopy Guideline: a risk-based approach to management and surveillance of cervical dysplasia. *Curr Oncol*, 2023, 30(6):5738–5768. <https://doi.org/10.3390/curroncol30060431> PMID: 37366914 PMID: PMC10297713
- Perkins RB, Guido RL, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M, Feldman S. Summary of current guidelines for

- cervical cancer screening and management of abnormal test results: 2016–2020. *J Womens Health (Larchmt)*, 2021, 30(1): 5–13. <https://doi.org/10.1089/jwh.2020.8918> PMID: 33464997 PMID: PMC8020523
- [16] Burness JV, Schroeder JM, Warren JB. Cervical colposcopy: indications and risk assessment. *Am Fam Physician*, 2020, 102(1):39–48. PMID: 32603071
- [17] Costa-Fagbemi M, Yakubu M, Meggetto O, Moffatt J, Walker MJ, Koné AP, Murphy KJ, Kupets R. Risk of cervical dysplasia after colposcopy care and risk-informed return to population-based screening: a systematic review. *J Obstet Gynaecol Can*, 2020, 42(5):607–624. <https://doi.org/10.1016/j.jogc.2019.05.017> PMID: 31679914
- [18] Salvadó A, Miralpeix E, Solé-Sedeno JM, Kanjou N, Lloveras B, Duran X, Mancebo G. Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: cytology and HPV genotyping. *Gynecol Oncol*, 2021, 162(3):569–574. <https://doi.org/10.1016/j.ygyno.2021.06.019> PMID: 34226019
- [19] Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J Natl Cancer Inst*, 2005, 97(14):1072–1079. <https://doi.org/10.1093/jnci/dji187> PMID: 16030305
- [20] Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas Hernández J, Glazer-Livson S, Jakobsson M, Joronen K, Kiviharju M, Louvanto K, Oksjoki S, Tähtinen R, Virtanen S, Nieminen P, Kyrgiou M, Kalliala I. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. *BMJ*, 2018, 360:k499. <https://doi.org/10.1136/bmj.k499> PMID: 29487049 PMID: PMC5826010
- [21] Lycke KD, Kahlert J, Damgaard RK, Eriksen DO, Bennetsen MH, Gravitt PE, Petersen LK, Hammer A. Clinical course of cervical intraepithelial neoplasia grade 2: a population-based cohort study. *Am J Obstet Gynecol*, 2023, 229(6):656.e1–656.e15. <https://doi.org/10.1016/j.ajog.2023.08.008> PMID: 37595822
- [22] Gori S, Frayle H, Pagan A, Soldà M, Romagnolo C, Insacco E, Laurino L, Matteucci M, Sordi G, Busato E, Zorzi M, Maggino T, Del Mistro A; CIN2 Study Working Group. Exploring conservative management for cervical intraepithelial neoplasia grade 2 in organised cervical cancer screening programmes: a multicentre study in Italy. *Fam Med Community Health*, 2024, 12(Suppl 2): e002595. <https://doi.org/10.1136/fmch-2023-002595> PMID: 38307701 PMID: PMC10840026

Corresponding authors

Claudia Florida Costea, Professor, MD, PhD, Discipline of Ophthalmology, Department of Surgery II, Faculty of Medicine, Grigore. T. Popa University of Medicine and Pharmacy, Iași, Romania; Department of Ophthalmology, Prof. Dr. Nicolae Oblu Emergency Clinical Hospital, 2 Ateneului Street, 700309 Iași, Romania; Phone +40744–972 648, e-mail: costea10@yahoo.com

Iustina Petra Solomon-Condriuc, MD, PhD, Department of Obstetrics and Gynecology, Faculty of Medicine, Grigore. T. Popa University of Medicine and Pharmacy, Iași, Romania; Doctoral School, Grigore. T. Popa University of Medicine and Pharmacy, 16 Universității Street, 700115 Iași, Romania; Phone +40740–119 866, e-mail: iustina_condriuc@yahoo.com

Received: August 22, 2024

Accepted: October 25, 2024